IDEXX is the dominant veterinary diagnostics platform (~45% global market share, ~60-65% North American in-clinic) operating a razor-and-blade model with 120,000+ installed premium analyzers driving high-margin recurring consumable and reference lab revenue with high-90s% retention rates. The integrated ecosystem (instruments + reference labs + cloud-native software + VetConnect PLUS data connectivity) creates a deeply embedded veterinary workflow moat that no competitor can replicate in breadth. FY2025 demonstrated the power of the model: 10% organic revenue growth and 31.6% operating margins with $1.06B FCF, driven by record inVue Dx placements and expanding same-store diagnostic utilization — even as clinical vet visits declined 1.7% YoY, proving IDEXX captures more revenue per visit through deeper diagnostic penetration.
| Scenario | Prob. | Target | Driver |
|---|---|---|---|
| Bull | 25% | $702.00 | Cancer Dx menu expansion (mast cell tumor, international lymphoma) drives >200bps acceleration in same-store diagnostic revenue per visit |
| Base | 50% | $635.00 | IDEXX executes 2026 guidance: revenue $4,632M-$4,720M with 40-90bps operating margin improvement |
| Bear | 25% | $445.00 | Clinical vet visit decline accelerates to -3% or worse, overwhelming same-store utilization growth |
Phase A/B deep research — competitive analysis and investment memo generation
Positioning skews toward near-term upside